Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
US Department of Justice
Boehringer Ingelheim
Harvard Business School

Generated: July 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204734

« Back to Dashboard
NDA 204734 describes FOSRENOL, which is a drug marketed by Shire Dev Llc and Shire Llc and is included in two NDAs. It is available from three suppliers. There are five patents protecting this drug and two Paragraph IV challenges. Additional details are available on the FOSRENOL profile page.

The generic ingredient in FOSRENOL is lanthanum carbonate. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the lanthanum carbonate profile page.

Summary for NDA: 204734

Therapeutic Class:Genitourinary Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 204734

Mechanism of ActionPhosphate Chelating Activity

Suppliers and Packaging for NDA: 204734

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
lanthanum carbonate
POWDER;ORAL 204734 NDA Shire US Manufacturing Inc. 54092-256 54092-256-02 9 CARTON in 1 PACKAGE (54092-256-02) > 10 POWDER in 1 CARTON (54092-256-01)
lanthanum carbonate
POWDER;ORAL 204734 NDA Shire US Manufacturing Inc. 54092-257 54092-257-02 9 CARTON in 1 CARTON (54092-257-02) > 10 POWDER in 1 CARTON (54092-257-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;ORALStrengthEQ 750MG BASE
Approval Date:Sep 24, 2014TE:RLD:Yes
Patent:7,465,465Patent Expiration:Aug 26, 2024Product Flag?YSubstance Flag?Delist Request?
Patent:8,980,327Patent Expiration:Dec 1, 2030Product Flag?YSubstance Flag?Delist Request?
Patent:9,023,397Patent Expiration:Dec 1, 2030Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Federal Trade Commission
US Army
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:

Google Plus